| Prev Close | 4.20 |
| Open | 4.24 |
| Day Low/High | 4.19 / 4.32 |
| 52 Wk Low/High | 1.71 / 5.71 |
| Volume | 998.04K |
| Avg Volume | 788.30K |
| Exchange | NASDAQ |
| Shares Outstanding | 50.97M |
| Market Cap | 214.07M |
| EPS | -1.80 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Verastem, Inc. (NASDAQ:VSTM), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 28th Annual Oppenheimer...
Verastem, Inc. (NASDAQ:VSTM), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the following investor...
Verastem, Inc. (NASDAQ:VSTM), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the year ended December 31, 2017 and...
Verastem, Inc. (Nasdaq:VSTM), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced the grant of stock options to eight new employees to purchase an...
Verastem, Inc. (NASDAQ:VSTM), focused on developing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 30 th Annual ROTH Conference on Monday, March...
Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced it has submitted a New Drug Application (NDA) to the U.
Verastem, Inc. (Nasdaq:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the grant of stock options to six new employees to purchase an...
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that a poster highlighting the synergistic effects of duvelisib in...
Verastem, Inc. (Nasdaq:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced its entry into an amendment to its Loan and Security Agreement with...
Verastem, Inc. (Nasdaq:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the appointment of Joseph Lobacki as Executive Vice President and...
After Roche's acquisition of Ignyta, I have high hopes for these other two names in 2018.
Are these names the next 'Ignytas'?
Investors in Verastem Inc saw new options begin trading this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VSTM options chain for the new February 2018 contracts and identified the following put contract of particular interest.
Verastem, Inc., (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the pricing of its previously announced underwritten public...
Verastem, Inc., (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that it intends to offer and sell $25 million of its common stock in...
Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the presentation of new preclinical and Phase 1 clinical data from...
Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the presentation of the results from the Phase 3 DUO study...
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, will present clinical data from the Phase 3 DUO study evaluating the efficacy and...
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the following upcoming investor...
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the third quarter ended September 30, 2017 and...
Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that four abstracts have been selected for presentation, including...
Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of patients with cancer, today announced that a meeting was held with the U.
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced payment of a $6 million milestone to Infinity Pharmaceuticals, Inc.
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the appointment of NgocDiep Le, MD, PhD, as Chief Medical Officer.
Verastem Inc., Pieris Pharmaceuticals and Intra-Cellular Therapies all have promising products.
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the Cantor Fitzgerald Global Healthcare Conference on Monday, September 25 th at...
Investors in Verastem Inc saw new options become available this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VSTM options chain for the new November 17th contracts and identified one put and one call contract of particular interest.
In recent trading, shares of Verastem Inc have crossed above the average analyst 12-month target price of $4.62, changing hands for $4.92/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
